Dexcom (DXCM) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Dexcom’s 2025 Share Repurchase Program, authorized by its Board of Directors, aims to buy back up to $750 million of its common stock by June 30, 2026. However, the program’s success in enhancing long-term share value is uncertain due to potential market volatility and other factors such as unfavorable market conditions and strategic opportunities. The company retains discretion over the timing and amount of repurchases, which may impact stock price and earnings per share. As of September 30, 2025, Dexcom has repurchased 2.4 million shares for $187.2 million, but the program’s future impact remains unpredictable.
The average DXCM stock price target is $90.33, implying 55.15% upside potential.
To learn more about Dexcom’s risk factors, click here.